Tag:
Vectibix
Latest Headlines
Latest Headlines
NICE votes nay for Lucentis, cancer meds; yea for Eliquis
As usual when the U.K. cost-effectiveness watchdogs convene, the latest NICE meeting delivered some newsworthy decisions. Perhaps the most notable: Eliquis , from Bristol-Myers Squibb ( $BMY ) and
Amgen drug flunks head-and-neck cancer trial
Amgen ( NASDAQ: AMGN ) released some rueful numbers on Vectibix today; the cancer drug failed a new trial in head-and-neck cancers. Adding Vectibix to chemo didn't improve overall survival, the company
Mixed results for Amgen's cancer drug Vectibix
Amgen is continuing its push to boost Vectibix by narrowing the drug's target market. The drugmaker announced results from a another Phase III trial, this time evaluating Vectibix as a second-line
Amgen touts KRAS results for Vectibix
Amgen is building up its case for broader use of Vectibix . Ironically, it's doing so by narrowing its focus on a subset of patients. In new trial results out today, Vectibix prolonged
FDA lets KRAS gene narrow drug use
Personalized cancer treatment took a giant step forward today. FDA has OK'd a label change for Erbitux and Vectibix, narrowing the indication for advanced colon cancer. The label now recommends the
Analyst: Amgen to score big on Vectibix
Amgen sales could get a significant boost from two upcoming Vectibix trials. Such a boost, in fact, that a company selling its biggest competitor--Erbitux--saw itself downgraded by Merrill Lynch.
ASCO: Narrow use of Erbitux, Vectibix
Once again, that celebrity of personalized cancer treatment--the KRAS gene--is on the red carpet. This time, it's the American Society of Clinical Oncology calling for colon cancer treatment to be
FDA advisers skeptical of retrospective genetic analysis
An FDA advisory committee took a dim view of two prominent developers' attempt to use a retrospective look at drug data to make a case that cancer drugs should be reserved for a specific population
Amgen asks FDA to narrow Vectibix use
To hear the experts tell it, the future of personalized medicine hangs in the balance today. An FDA advisory panel is set to talk over standards for linking genetic tests with cancer drugs. How
